SU1516013A3 - Method of producing thermally stable crystalline sulfuric acid-additive salts of 7-/-alpha-(2-aminothiazol-4-yl)-alpha-(z)-methoxyiminoacetamido/-3-/(1-methyl-1-pyrrolidinio)-methyl/-3-cephem-4-carboxylate - Google Patents
Method of producing thermally stable crystalline sulfuric acid-additive salts of 7-/-alpha-(2-aminothiazol-4-yl)-alpha-(z)-methoxyiminoacetamido/-3-/(1-methyl-1-pyrrolidinio)-methyl/-3-cephem-4-carboxylate Download PDFInfo
- Publication number
- SU1516013A3 SU1516013A3 SU864027914A SU4027914A SU1516013A3 SU 1516013 A3 SU1516013 A3 SU 1516013A3 SU 864027914 A SU864027914 A SU 864027914A SU 4027914 A SU4027914 A SU 4027914A SU 1516013 A3 SU1516013 A3 SU 1516013A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- methyl
- sulfuric acid
- cephem
- alpha
- carboxylate
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 9
- 238000000034 method Methods 0.000 title claims abstract description 4
- 239000000654 additive Substances 0.000 title claims description 3
- -1 1-methyl-1-pyrrolidinio Chemical class 0.000 title description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000010949 copper Substances 0.000 claims abstract description 4
- 238000002425 crystallisation Methods 0.000 claims abstract description 4
- 230000008025 crystallization Effects 0.000 claims abstract description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229910052802 copper Inorganic materials 0.000 claims abstract description 3
- 229910052759 nickel Inorganic materials 0.000 claims abstract description 3
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 239000000843 powder Substances 0.000 claims abstract 2
- 239000011541 reaction mixture Substances 0.000 claims abstract 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 18
- 150000002500 ions Chemical class 0.000 claims description 5
- 230000000996 additive effect Effects 0.000 claims description 2
- 229930186657 Lat Natural products 0.000 claims 1
- 230000000052 comparative effect Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- HVFLCNVBZFFHBT-KTNPMIOTSA-N (6R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound NC=1SC=C(N=1)/C(/C(=O)NC1[C@@H]2N(C(=C(CS2)C[N+]2(CCCC2)C)C(=O)[O-])C1=O)=N/OC HVFLCNVBZFFHBT-KTNPMIOTSA-N 0.000 abstract 2
- 229930186147 Cephalosporin Natural products 0.000 abstract 1
- 239000012736 aqueous medium Substances 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 229940124587 cephalosporin Drugs 0.000 abstract 1
- 150000001780 cephalosporins Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000000243 solution Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229960003646 lysine Drugs 0.000 description 2
- 239000006069 physical mixture Substances 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
- C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Изобретение относитс к гетероциклическим соединени м, в частности к получению термически стабильной кристаллической аддитивной соли с серной кислотой 7-[α-(2-аминотиазол-4-ил)-α-(Z)-метоксииминоацетамидо]-3-[(1-метил-1-пирролидинио)-метил]-3-цефем-4-карбоксилата, имеющей диффракционную рентгеновскую решетку, сн тую дл порошка на медной трубке с никелевым фильтром (CU:NI) с определенными значени ми межплоскостных рассто ний D и относительных интенсивностей 1/1°, котора может найти применение в медицине. Цель - разработка способа получени новой кристаллической формы цефалоспоринового антибиотика. Получение целевого продукта ведут реакцией амфотерного 7-[α-(2-аминотиазол-4-ил)-α-(Z)-метоксииминоацетамидо]-3-[(1-метил-1-пирролидинио)-метил]-3-цефем-4-карбоксилата с концентрацией 100-200 мг/мл с H2SO4 (1-2 мол. экв.) в водной среде. Затем инициируют кристаллизацию целевого продукта из реакционной смеси и выдел ют его. 1 табл.The invention relates to heterocyclic compounds, in particular to the preparation of a thermally stable crystalline addition salt with 7- [α- (2-aminothiazol-4-yl) -α- (Z) methoxyiminoacetamido] -3 - [(1-methyl -1-pyrrolidinio) -methyl] -3-cephem-4-carboxylate, having a diffraction X-ray lattice, removed for powder on a copper tube with a nickel filter (CU: NI) with specific values of interplanar spacing D and relative intensities 1 / 1 °, which can be used in medicine. The goal is to develop a method for obtaining a new crystalline form of a cephalosporin antibiotic. The production of the target product is carried out by the reaction of amphoteric 7- [α- (2-aminothiazol-4-yl) -α- (Z) -methoxyiminoacetamido] -3 - [(1-methyl-1-pyrrolidinio) methyl] -3-cephem- 4-carboxylate with a concentration of 100-200 mg / ml with H 2 SO 4 (1-2 mol. Eq.) In an aqueous medium. The crystallization of the desired product from the reaction mixture is then initiated and recovered. 1 tab.
Description
1,5 г амфотерных ионов медленно добавл ют в 10 мл энергетично перемешиваемого 1 н, раствора серной кислоты (1,59 моль-экв) при 20-26 С, Получают раствор. Затем кристаллизацию инициируют при помощи затравки с использованием кристаллической аддитивной соли серной кислоты и вьщержи вают кристаллическую массу в виде шлама в течение 0,5 ч. Далее кристаллы отдел ют при помощи вакуумной фильтрации, промывают при помощи 3 мл смеси ацетона: вода (1:1 по объему ) и двух порций по 5 мл ацетона; затем осуществл ют вакуумную сугоку при 40-50 0 в течение ночи,1.5 g of amphoteric ions are slowly added to 10 ml of energetically stirred 1 N, sulfuric acid solution (1.59 mol eq) at 20-26 ° C. A solution is obtained. Then, the crystallization is initiated by means of a seed using a crystalline sulfuric acid addition salt, and the crystalline mass is held in the form of a slurry for 0.5 h. Next, the crystals are separated by vacuum filtration, washed with 3 ml of acetone: water (1: 1 by volume) and two servings of 5 ml of acetone; then vacuum sugoku is performed at 40-50 ° overnight,
Выход составл ет 1,3 г аддитивной соли серной кислоты.The yield is 1.3 g of the sulfuric acid addition salt.
Элементный анализElemental analysis
Рассчитано, .%: С 39-,44; И 4,53; N 14,52; S -16,62; - не обнаружена ,Calculated,%: C 39-, 44; And 4.53; N 14.52; S -16.62; - not detected
. .
Найдено, %: С 38,91; Н 4,57; N 14,64; S 16,71; 1,42.Found,%: C 38.91; H 4.57; N 14.64; S 16.71; 1.42.
Пример 2. Получение аддитивной соли серной кислоты,Example 2. Obtaining additive sulfuric acid,
1,5 г амфотерных ионов раствор ют в 5 мл воды, Б полученный раствор добавл ют при перемешивании 5 мл 1 М раствора HjiSO. Затем кристаллизацию инициируют при помощи затравки кристаллической аддитивной соли кислоты, далее кристаллы выдерживают в гпламе в течение 0,5 ч. Затем кристаллы отдел ют при помощи вакуумной фильтрации, промывают 3 мл смеси ацетон:вода (1:1 по объему) и двум порци ми по 5 мл ацетона; затем сушат под вакуумом при 40-50 С в течение ночи.1.5 g of amphoteric ions are dissolved in 5 ml of water; B, the resulting solution is added with stirring 5 ml of 1 M solution of HjiSO4. Then, the crystallization is initiated by priming the crystalline acid addition salt, then the crystals are incubated in hplame for 0.5 h. Then the crystals are separated by vacuum filtration, washed with 3 ml of a mixture of acetone: water (1: 1 by volume) and two portions 5 ml of acetone; then dried under vacuum at 40-50 ° C overnight.
Выход составл ет 1,3 г аддитивной соли серной кислоты.The yield is 1.3 g of the sulfuric acid addition salt.
Дифракционную решетку порошка в рентгеновских лучах кристаллической сульфатной соли (-(2-аминотиазол- 4-ил)-о/-(Е) -метоксиминоацетамидоД- 3 (1-метил-1-пирролидинио)-метил - : З-цефем-4-карбоксилата, полученной в соответствии с примерами 1 и 2, определ ли при помошд дифрактометра дл порошкообразных материалов типа Ригаку с использованием в качестве мишеш дл рентгеновских лучей медной трубки, никелевого фильтра и пробы, содержащейс в стекл нной чашке. Скорость сканировани составл ла 2/мин в области изменени отX-ray diffraction grating of crystalline sulfate salt (- (2-aminothiazol-4-yl) -o / - (E) -methoxyminoacetamido D-3 (1-methyl-1-pyrrolidino) -methyl -: Z-cepham-4- the carboxylate prepared according to examples 1 and 2 was determined using a diffractometer for powdered Rigaku materials using a copper tube, a nickel filter and a sample contained in a glass cup as x-ray targets. The scan rate was 2 / min in the field of change from
4four
40, при этом механически запи40, while mechanically recording
00
5five
00
5five
00
5five
00
5five
сывали диаграмму с тем, чтобы зафиксировать углы с максимальной дифракцией . На основании этих данных определ ли промежутки (d) и относитель- .ные интенсивности (1/1°), Эти данные приведены ниже, d-пpoмeжyткИ| А 1/1°, %The diagram was drawn in order to fix the angles with the maximum diffraction. On the basis of these data, the intervals (d) and relative intensities (1/1 °) were determined. These data are given below, d-intercept | А 1/1 °,%
9,201009,20100
6,89506.8950
5,50285.5028
5,09225.0922
4,50384.5038
4,41444,4144
4,19644.1964
3,78383.7838
3,64443.6444
3,39253.3925
3,31313.3131
3,15473.1547
Пример 3. Изучение стабильности при повышенных температурах .Example 3. The study of stability at elevated temperatures.
Термическую стабильность определ ли при хранении композиций в сухих контейнерах при различных температурах, а изменение эффективности определ ли с использованием ВЧЖХ,The thermal stability was determined by storing the compositions in dry containers at different temperatures, and the change in efficiency was determined using HPLC,
Полученные результаты представлены в таблице.(увеличение эффективности указано знаком плюс перед числом; потер эффективности менее 10% в течение 2-4 недель при 45-56 С в общем случае указывает на снижение эффективности менее чем на 10% в течение 2-3 лет при комнатной температуре ) ,The results are presented in the table. (The increase in efficiency is indicated by a plus sign in front of a number; a loss of efficiency of less than 10% for 2-4 weeks at 45-56 C generally indicates a decrease in efficiency of less than 10% for 2-3 years with room temperature)
Пример 4, Испытание физических смесей.Example 4, Testing physical mixtures.
Физические смеси получали из кристаллической аддитивной соли серной кислоты с тринатрий ортофосфатом, бикарбонатом натри , Ь(+)-лизином и Ь()-аргинином. Основани добавл ли в таких пропорци х, чтобы обеспечить значени рН при разбавлении смеси водой до активности амфотерных ионов 250 мг/кг (которую определ ли при помощи ВЧЖХ) в следующих преде- лах:тринатрий ортофосфат (рН 6,0); бикарбонат натри (рН 6,0); Lr-(-f)- лизин (рН 6,0); L--(+)-аргинин (рН 6,0/,Physical mixtures were obtained from a crystalline sulfuric acid addition salt with trisodium orthophosphate, sodium bicarbonate, L (+) - lysine and L () - arginine. The bases were added in such proportions as to ensure that the pH of the mixture was diluted with water until amphoteric ions activity was 250 mg / kg (as determined by HPLC) in the following limits: trisodium orthophosphate (pH 6.0); sodium bicarbonate (pH 6.0); Lr - (- f) - lysine (pH 6.0); L - (+) - arginine (pH 6.0 /,
Композиции дл инъекций получки с использованием стерильной воды, чтобы довести активность амфотер5 1516013, 6Injection compositions of wages using sterile water to bring amphoter5 activity 1516013, 6
ных ионов до 250 мг/мл, которую оп-d, А ions up to 250 mg / ml, which op-d, A
редел ли при помощи ВЧЖХ, Трудностей. 9,20 100Determined by HPLC, Difficulties. 9.20 100
с растворимостью не было, 50with solubility was not 50
Инъекции проводили (в дозе 100 мг/кг) 5,50 28Injections were performed (at a dose of 100 mg / kg) 5.50 28
внутримышечным способом кроликам,5,09 22by intramuscular method to rabbits, 5.09 22
при этом болезненные ощущени были в4,50 38while the pain was 4.50 38
допустимых пределах. Минимальные4,41 А4allowable limits. Minimum4,44 A4
болезненные ощущени наблюдали при4,19 63pain sensations observed at 4,19 63
применении композиции, содержащей ар-Ю 3,78 38the use of a composition containing ar-S 3.78 38
гинин,3,64 4Аginin, 3.64 4A
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76223585A | 1985-08-05 | 1985-08-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1516013A3 true SU1516013A3 (en) | 1989-10-15 |
Family
ID=25064475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU864027914A SU1516013A3 (en) | 1985-08-05 | 1986-08-04 | Method of producing thermally stable crystalline sulfuric acid-additive salts of 7-/-alpha-(2-aminothiazol-4-yl)-alpha-(z)-methoxyiminoacetamido/-3-/(1-methyl-1-pyrrolidinio)-methyl/-3-cephem-4-carboxylate |
Country Status (34)
| Country | Link |
|---|---|
| JP (1) | JPH0615548B2 (en) |
| KR (1) | KR930003121B1 (en) |
| AR (1) | AR243894A1 (en) |
| AT (1) | AT390957B (en) |
| AU (1) | AU597262B2 (en) |
| BE (1) | BE905219A (en) |
| CA (1) | CA1284994C (en) |
| CH (1) | CH675581A5 (en) |
| CS (2) | CS276849B6 (en) |
| CY (1) | CY1614A (en) |
| DD (2) | DD254941A5 (en) |
| DE (1) | DE3626375A1 (en) |
| DK (1) | DK162053C (en) |
| EG (1) | EG18003A (en) |
| ES (1) | ES2002112A6 (en) |
| FI (1) | FI84484C (en) |
| FR (1) | FR2585705B1 (en) |
| GB (1) | GB2179936B (en) |
| GR (1) | GR862055B (en) |
| HK (1) | HK99691A (en) |
| HU (1) | HU196602B (en) |
| IE (1) | IE59222B1 (en) |
| IL (1) | IL79608A (en) |
| IT (1) | IT1197067B (en) |
| LU (2) | LU86540A1 (en) |
| MY (1) | MY102212A (en) |
| NL (1) | NL8601991A (en) |
| OA (1) | OA08672A (en) |
| PT (1) | PT83134B (en) |
| SE (1) | SE469633B (en) |
| SG (1) | SG79791G (en) |
| SU (1) | SU1516013A3 (en) |
| YU (1) | YU45793B (en) |
| ZA (1) | ZA865842B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2136685C1 (en) * | 1993-03-12 | 1999-09-10 | Фармация Энд Апджон Компани | Crystalline free cefthiofuric acid, composition on said and method of its synthesis |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4959469A (en) * | 1984-12-27 | 1990-09-25 | Banyu Pharmaceutical Company, Ltd. | Crystalline cephalosporin compounds |
| US4883868A (en) * | 1984-12-27 | 1989-11-28 | Banyu Pharmaceutical Co., Ltd. | 7-amino-3-(substituted isoindolinium)methyl-3-cephem derivatives |
| US5244891A (en) * | 1985-08-05 | 1993-09-14 | Bristol-Myers Squibb Company | Injectable compositions of cefepime dihydrochloride hydrate |
| US4910301A (en) * | 1985-08-05 | 1990-03-20 | Bristol-Myers Company | Cefepime cephalosporin salts |
| US4808617A (en) * | 1985-12-18 | 1989-02-28 | Bristol-Myers Company | Lyophilized or precipitated cephalosporin zwitterion and salt combination |
| ATE97668T1 (en) * | 1987-06-25 | 1993-12-15 | Banyu Pharma Co Ltd | CRYSTALLINE CEPHALOSPORIN COMPOSITIONS, PROCESSES AND INTERMEDIATE PRODUCTS FOR THEIR MANUFACTURE. |
| JPH02101081A (en) * | 1988-10-08 | 1990-04-12 | Meiji Seika Kaisha Ltd | Crystalline dihydrochloride of cephalosporin derivative and production thereof |
| CA2011116C (en) * | 1989-03-06 | 1999-11-16 | Murray A. Kaplan | Lyophilized bmy-28142 dihydrochloride for parenteral use |
| CA2101571A1 (en) * | 1992-09-08 | 1994-03-09 | Elizabeth A. Garofalo | Crystalline dihydrate of a cephalosporin dihydrate salt and injectable compositions thereof |
| EP0638573A1 (en) * | 1993-08-10 | 1995-02-15 | Lucky Ltd. | Crystalline hydrates of cephalosporin and process for preparation thereof |
| EP1699804B1 (en) | 2003-12-23 | 2008-02-06 | Sandoz Gmbh | Process for production of intermediates for use in cefalosporin synthesis |
| WO2008056221A2 (en) * | 2006-11-06 | 2008-05-15 | Orchid Chemicals & Pharmaceuticals Limited | Crystalline sulfate salt of cephalosporin antibiotic |
| DE102012101680A1 (en) * | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Pharmaceutical preparation containing an antiviral dihydroquinazoline derivative |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55151588A (en) * | 1979-05-14 | 1980-11-26 | Takeda Chem Ind Ltd | Preparation of cephalosporin salt crystal |
| US4406899A (en) * | 1982-03-04 | 1983-09-27 | Bristol-Myers Company | Cephalosporins |
| CA1213882A (en) * | 1982-03-04 | 1986-11-12 | Jun Okumura | Cephalosporins |
| US4525473A (en) * | 1983-03-30 | 1985-06-25 | Bristol-Myers Company | Cephalosporins |
| DE3419015A1 (en) * | 1984-05-22 | 1985-11-28 | Bayer Ag, 5090 Leverkusen | METHOD FOR PRODUCING CEPHALOSPORINES |
| GB2165245B (en) * | 1984-10-01 | 1988-05-25 | Glaxo Group Ltd | Chemical compounds |
| GB8424692D0 (en) * | 1984-10-01 | 1984-11-07 | Glaxo Group Ltd | Chemical compounds |
-
1986
- 1986-07-28 CA CA000514766A patent/CA1284994C/en not_active Expired - Lifetime
- 1986-07-28 FR FR8610892A patent/FR2585705B1/en not_active Expired
- 1986-07-29 AR AR86304717A patent/AR243894A1/en active
- 1986-07-30 AU AU60694/86A patent/AU597262B2/en not_active Expired
- 1986-07-31 YU YU137186A patent/YU45793B/en unknown
- 1986-08-01 IE IE207886A patent/IE59222B1/en not_active IP Right Cessation
- 1986-08-01 FI FI863155A patent/FI84484C/en not_active IP Right Cessation
- 1986-08-04 LU LU86540A patent/LU86540A1/en unknown
- 1986-08-04 LU LU88574C patent/LU88574I2/en unknown
- 1986-08-04 IT IT21409/86A patent/IT1197067B/en active Protection Beyond IP Right Term
- 1986-08-04 IL IL79608A patent/IL79608A/en not_active IP Right Cessation
- 1986-08-04 GB GB8618989A patent/GB2179936B/en not_active Expired
- 1986-08-04 PT PT83134A patent/PT83134B/en unknown
- 1986-08-04 CS CS903570A patent/CS276849B6/en unknown
- 1986-08-04 ZA ZA865842A patent/ZA865842B/en unknown
- 1986-08-04 CS CS865827A patent/CS276717B6/en unknown
- 1986-08-04 NL NL8601991A patent/NL8601991A/en not_active Application Discontinuation
- 1986-08-04 JP JP61183288A patent/JPH0615548B2/en not_active Expired - Lifetime
- 1986-08-04 DE DE19863626375 patent/DE3626375A1/en not_active Ceased
- 1986-08-04 CH CH3117/86A patent/CH675581A5/de not_active IP Right Cessation
- 1986-08-04 SE SE8603308A patent/SE469633B/en not_active IP Right Cessation
- 1986-08-04 DK DK371886A patent/DK162053C/en not_active IP Right Cessation
- 1986-08-04 GR GR862055A patent/GR862055B/en unknown
- 1986-08-04 BE BE07217010A patent/BE905219A/en not_active IP Right Cessation
- 1986-08-04 SU SU864027914A patent/SU1516013A3/en active
- 1986-08-05 AT AT0211086A patent/AT390957B/en not_active IP Right Cessation
- 1986-08-05 HU HU863376A patent/HU196602B/en unknown
- 1986-08-05 ES ES8600872A patent/ES2002112A6/en not_active Expired
- 1986-08-05 KR KR1019860006445A patent/KR930003121B1/en not_active Expired - Lifetime
- 1986-08-05 OA OA58918A patent/OA08672A/en unknown
- 1986-08-05 DD DD86293433A patent/DD254941A5/en unknown
-
1987
- 1987-09-29 MY MYPI87002279A patent/MY102212A/en unknown
-
1988
- 1988-03-30 DD DD88314213A patent/DD268395A5/en unknown
-
1989
- 1989-08-04 EG EG489/86A patent/EG18003A/en active
-
1991
- 1991-10-02 SG SG797/91A patent/SG79791G/en unknown
- 1991-12-05 HK HK996/91A patent/HK99691A/en not_active IP Right Cessation
-
1992
- 1992-07-10 CY CY1614A patent/CY1614A/en unknown
Non-Patent Citations (1)
| Title |
|---|
| Па тент.. US № 4406899. кл. 424-246, опублик. 1985.., . * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2136685C1 (en) * | 1993-03-12 | 1999-09-10 | Фармация Энд Апджон Компани | Crystalline free cefthiofuric acid, composition on said and method of its synthesis |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU1516013A3 (en) | Method of producing thermally stable crystalline sulfuric acid-additive salts of 7-/-alpha-(2-aminothiazol-4-yl)-alpha-(z)-methoxyiminoacetamido/-3-/(1-methyl-1-pyrrolidinio)-methyl/-3-cephem-4-carboxylate | |
| KR950003612B1 (en) | Cephalosporin salts and injectable compositions | |
| RU1787158C (en) | Method of cephem compound or theirs additive salts with acids synthesis | |
| CS244940B2 (en) | Production method of /s/-epimeres of esters of 7beta-malonamido -7alfa-methoxy-3-tetrazolythiomethyl-1-dethia-loxa-3-cefem-4-carboxyl acid | |
| KR910000420B1 (en) | Method for preparing crystalline cefem-acid addition salt | |
| JPS6016994A (en) | Cephalosporin derivative | |
| AU621040B2 (en) | Crystallized cephem-acid addition salts, and a process for the preparation thereof | |
| US4727070A (en) | 3-Propenzl cephalosporin isomer separation process and derivative | |
| US5409918A (en) | Crystalline cephem acid addition salts and process for their preparation | |
| CN106220648B (en) | A kind of synthesis of tertbutyloxycarbonyl Cefcapene diisopropylamine and purification process | |
| US4994451A (en) | Cephalosporin salts and injectable compositions | |
| AU2006300882B2 (en) | Crystalline sodium salt of cephalosporin antibiotic | |
| JPS6115885A (en) | Manufacture of ceftazidime | |
| US4124762A (en) | 7-[(Pyridylthiomethyl)phenyl]acetamido-cephalosporin derivatives | |
| IE48572B1 (en) | Production of sodium cefamandole | |
| KR810000909B1 (en) | Process for preparing cephalosporin derivatives | |
| SU571187A3 (en) | Method of obtaining derivatives of 2-aminomethyl-4,6-digahaloidophenol derivatives | |
| JPS58183695A (en) | Active cefuroxime derivative for oral administration, manufacture and medicinal composition | |
| PL51904B1 (en) | ||
| NO780835L (en) | PROCEDURE FOR PREPARATION OF CEPHALOSPORINE DERIVATIVES |